| ABG Sundal Collier | UK | Viktor Sundberg | Reports are proprietary. Contact ABG |
| Aktieinfo | DK | John Stihøj | Reports and more info |
| Aktiespararna | SWE | Sten Westerberg | Reports and more info |
| Kapital Partner | DK | Jesper Ilsøe | Reports are proprietary. Contact Kapital |
| Oppenheimer | UK | Jay Olson | Reports are proprietary. Contact Oppenheimer |
| Redeye | UK | Anders Hedlund | Reports and more info |
| Date | Analyst | Language | Analyst Report |
|---|---|---|---|
| 2020/12/21 | Oppenheimer | UK | Unmet Needs Met with Tesomet; Initiate at Outperform |
| 2020/12/16 | Kapital Partner | DK | From the ugly duckling to the swan of 2021 |
| 2020/12/08 | Aktiespararna | SWE | Analysis Saniona: "Great potential in the research company" |
| 2020/12/03 | Aktieinfo | DK | The focus is on Tesomet in Prader-Willi and hyothalamic obesity... |
| 2020/11/30 | Redeye | UK | Saniona Q3’20: Our Comment |
| 2020/11/24 | Redeye | UK | Saniona: Tesomet Potential Reinforced |
| 2020/11/24 | ABG Sundal Collier | UK | Open-label extension confirms efficacy in HO |
| 2020/11/06 | Redeye | UK | Short-term Setback, Long-term Opportunities |
| 2020/10/16 | Redeye | UK | Key Takeaways after Neurology Seminar CNS |
| 2020/10/12 | Redeye | UK | Comment on FDA Feedback |
| 2020/09/25 | Redeye | UK | Strengthen Financials Further |
| 2020/09/21 | Aktieinfo | DK | Two products are in Phase 2... |
| 2020/09/03 | Redeye | UK | It’s a New Case (But Currently in Two Minds) |
| 2020/08/20 | ABG Sundal Collier | UK | Setting Sail Towards Pivotal Studies |
| 2020/08/17 | Aktiespararna | SWE | Analysis Saniona: "Revaluation pending FDA" |